Drug Approval | June 24, 2022
Rivaroxaban approved in Japan for patients with PAD after revascularisation
It´s the first trial to demonstrate the benefits of dual pathway inhibition
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
Bringing next-gen cannabinoid therapeutics to cancer patients
Subscribe To Our Newsletter & Stay Updated
